{
    "title": "Novartis expects improved earnings at generics unit Sandoz",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11027285/Novartis-expects-improved-earnings-generics-unit-Sandoz.html",
    "date": "2022-07-19",
    "keywords": [
        "novartis",
        "drug",
        "growth",
        "sandoz",
        "year",
        "future",
        "statement",
        "guidance",
        "core",
        "income",
        "company",
        "finance",
        "chief",
        "drag",
        "value",
        "market",
        "sale",
        "bolton",
        "drugmaker",
        "arm",
        "review",
        "group",
        "midsingle",
        "digit",
        "percentage",
        "range",
        "update",
        "end",
        "quarter",
        "business",
        "prescription",
        "harry",
        "call",
        "change",
        "ownership",
        "mean",
        "pharma",
        "groupwide",
        "cost",
        "cutting",
        "scheme",
        "implementation",
        "model",
        "secondquarter",
        "analyst",
        "estimate",
        "refinitiv",
        "poll",
        "dollar",
        "decline",
        "production",
        "precision",
        "cancer",
        "addition",
        "competition",
        "gilenya",
        "revenue",
        "heart",
        "failure",
        "entresto",
        "touch",
        "psoriasis",
        "cosentyx",
        "line",
        "consensus",
        "ceo",
        "vas",
        "narasimhan",
        "efficiency",
        "cash",
        "stake",
        "roche",
        "rival",
        "worth",
        "spending",
        "power",
        "development",
        "funding",
        "kirsch",
        "view",
        "burger",
        "rachel",
        "coghill",
        "louise"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}